PF06869206
|
|
|
- CAS號:
- 2227425-05-8
- 英文名:
- PF06869206
- 英文別名:
- CS-2762;PF06869206;PF-06869206;PF-06869206, 10 mM in DMSO;PF-06869206; PF 06869206; PF06869206;inhibit,PF-06869206,Na+ channels,Sodium Channel,Na channels,PF 06869206,Inhibitor,PF06869206;(S)-3-Chloro-7-(2-(hydroxymethyl)morpholino)-2-methyl-5-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridine-6-carbonitrile;1H-Pyrrolo[3,2-b]pyridine-6-carbonitrile, 3-chloro-7-[(2S)-2-(hydroxymethyl)-4-morpholinyl]-2-methyl-5-(trifluoromethyl)-
- 中文名:
- PF06869206
- 中文別名:
- 化合物PF-06869206;化合物PF-06869206,10 MM DMSO 溶液;(S)-3-氯-7-(2-(羥甲基)嗎啉)-2-甲基-5-(三氟甲基)-1H-吡咯并[3,2-B]吡啶-6-腈
- CBNumber:
- CB04187431
- 分子式:
- C15H14ClF3N4O2
- 分子量:
- 374.75
- MOL File:
- 2227425-05-8.mol
|
|
|
PF06869206化學(xué)性質(zhì)
-
沸點:
-
599.2±50.0 °C(Predicted)
-
|
-
密度:
-
1.57±0.1 g/cm3(Predicted)
-
|
-
儲存條件:
-
2-8°C
-
|
-
溶解度:
-
DMF: 1 mg/mL; DMSO: 1mg/mL; Ethanol: 10mg/mL; Ethanol:PBS (pH 7.2) (1:3): 0.25 mg/mL
-
|
-
形態(tài):
-
A crystalline solid
-
|
-
酸度系數(shù)(pKa):
-
11.78±0.40(Predicted)
-
|
-
顏色:
-
White to off-white
-
|
-
InChI:
-
InChI=1S/C15H14ClF3N4O2/c1-7-10(16)11-12(21-7)13(23-2-3-25-8(5-23)6-24)9(4-20)14(22-11)15(17,18)19/h8,21,24H,2-3,5-6H2,1H3/t8-/m0/s1
-
|
-
InChIKey:
-
ATFQBBCQZKVZJN-QMMMGPOBSA-N
-
|
-
SMILES:
-
C12C(Cl)=C(C)NC1=C(N1CCO[C@H](CO)C1)C(C#N)=C(C(F)(F)F)N=2
-
|
PF06869206性質(zhì)、用途與生產(chǎn)工藝
PF-06869206 是一種有效的，具有口服活性的選擇性磷酸鈉協(xié)同轉(zhuǎn)運蛋白 NaPi2a (SLC34A1) 抑制劑，IC50 為 380 nM。
IC50: 380 nM (NaPi2a/SLC34A1)
PF-06869206 shows a balance of attributes with 380 nM NaPi2a inhibition potency, excellent subtype selectivity, and acceptable aqueous solubility (46 μM). PF-06869206 is profiled for potency in the rodent NaPi2a and NaPi2c cell lines. PF-06869206 shows comparable submicromolar activity for the human, rat, and mouse NaPi2a isoforms with IC
50
s of 0.4±0.047 μM and 0.54±0.099 μM for rat NaPi2a and mouse NaPi2a, respectively.
PF-06869206 is evaluated in rodent PK studies to determine suitability for in vivo pharmacology exploration. Results show moderate clearance in both rat and mouse. Oral bioavailability at 5 mg/kg is good in rat and moderate in mouse. At higher oral doses of 50 mg/kg, supraproportional increases in exposure are observed in both species, suggestive of saturation of clearance. PF-06869206 has moderate terminal elimination half-life (t
1/2
=1.35 h, and 0.75 h for Wistar-Han rats (10 mg/kg, iv), and C57BL6 mice (1 mg/kg, iv)). Furthermore, permeability is good (14×10
-6
cm/s), and rat liver microsome (RLM) clearance is low (<14 μL/min/mg; HLM=39 μL/min/mg).
PF06869206
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS編號 | 包裝 | 價格 |
|---|
| 2026/07/06 | S0036 | PF06869206
PF-06869206 | 2227425-05-8 | 5mg | 5544.63元 |
| 2026/07/06 | S0036 | PF06869206
PF-06869206 | 2227425-05-8 | 25mg | 16699.4元 |
2227425-05-8, PF06869206 相關(guān)搜索:
- 抑制劑
- 藥靶配體
- 化合物PF-06869206,10 MM DMSO 溶液
- 化合物PF-06869206
- (S)-3-氯-7-(2-(羥甲基)嗎啉)-2-甲基-5-(三氟甲基)-1H-吡咯并[3,2-B]吡啶-6-腈
- 2227425-05-8
- PF-06869206, 10 mM in DMSO
- inhibit,PF-06869206,Na+ channels,Sodium Channel,Na channels,PF 06869206,Inhibitor,PF06869206
- (S)-3-Chloro-7-(2-(hydroxymethyl)morpholino)-2-methyl-5-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridine-6-carbonitrile
- 1H-Pyrrolo[3,2-b]pyridine-6-carbonitrile, 3-chloro-7-[(2S)-2-(hydroxymethyl)-4-morpholinyl]-2-methyl-5-(trifluoromethyl)-
- PF-06869206; PF 06869206; PF06869206
- CS-2762
- PF-06869206
- PF06869206